← Back to Clinical Trials
Recruiting NCT06974279

NCT06974279 Post-Stroke Aphasia TMS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06974279
Status Recruiting
Phase
Sponsor Medical College of Wisconsin
Condition Aphasia
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-09-01
Primary Completion 2036-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Precision TMS with SFAControl TMS with SFA

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-09-01 with a primary completion date of 2036-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigator proposes to examine the effects of excitatory transcranial magnetic stimulation (TMS) combined with semantic feature analysis (SFA) language therapy to improve word-finding abilities in stroke survivors with aphasia (SWA).

Eligibility Criteria

Inclusion Criteria: * Diagnosed with left hemisphere stroke * Consent date \>= 1 month after stroke onset * Fluent in English * 18 years of age or older Exclusion Criteria: * Severe cognitive, auditory or visual impairments that would preclude cognitive and language testing * Presence of major untreated or unstable psychiatric disease (e.g. schizophrenia, bipolar disease) * A chronic medical condition that is not treated or is unstable * The presence of cardiac stimulators or pacemakers or intracardiac lines, neurostimulators, medication infusion device, any other implants near the scalp (e.g., cochlear implants) or in the eye, metal in the body (e.g., splinters, fragments, clips) * Pregnancy * History of skull fractures, or skin diseases * History of ongoing or unmanaged seizures * Presence of factors that potentially decrease seizure thresholds: on pro-convulsant medications, untreated sleep deprivation or insomnia, ongoing alcoholism or illegal drug abuse (e.g., cocaine or MDMA users) * History of dyslexia or other developmental learning disabilities

Contact & Investigator

Central Contact

Sidney Schoenrock, MA

✉ sschoenrock@mcw.edu

📞 414-955-7579

Frequently Asked Questions

Who can join the NCT06974279 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Aphasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06974279 currently recruiting?

Yes, NCT06974279 is actively recruiting participants. Contact the research team at sschoenrock@mcw.edu for enrollment information.

Where is the NCT06974279 trial being conducted?

This trial is being conducted at Milwaukee, United States.

Who is sponsoring the NCT06974279 clinical trial?

NCT06974279 is sponsored by Medical College of Wisconsin. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology